AQR Capital Management
IBRX icon

AQR Capital Management’s ImmunityBio IBRX Stock Holding History

AQR Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.95M Buy
222,862
+156,315
+235% +$1.18M ﹤0.01% 2638
2026
Q1 		$510K Buy
66,547
+19,922
+43% +$136K ﹤0.01% 3109
2025
Q4 		$92.3K Sell
46,625
-57,154
-55% -$129K ﹤0.01% 3466
2025
Q3 		$255K Sell
103,779
-55,383
-35% -$143K ﹤0.01% 3157
2025
Q2 		$420K Buy
159,162
+114,714
+258% +$308K ﹤0.01% 2708
2025
Q1 		$134K Buy
44,448
+29,297
+193% +$88.8K ﹤0.01% 2960
2024
Q4 		$38.8K Sell
15,151
-39,736
-72% -$166K ﹤0.01% 2825
2024
Q3 		$204K Buy
54,887
+6,435
+13% +$29.8K ﹤0.01% 2558
2024
Q2 		$306K Buy
48,452
+29,727
+159% +$196K ﹤0.01% 2259
2024
Q1 		$101K Buy
+18,725
New +$84.8K ﹤0.01% 2338
2021
Q1 		– Sell
-45,338
Closed -$604K – 2225
2020
Q4 		$604K Sell
45,338
-15,555
-26% -$150K ﹤0.01% 1718
2020
Q3 		$422K Buy
+60,893
New +$607K ﹤0.01% 1800

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AQR Capital Management's IBRX Position: Q2 2026 in Review

AQR Capital Management increased its ImmunityBio (IBRX) stake by 235% in Q2 2026, buying an estimated $1.18M and bringing the position to 222,862 shares worth $1.95M. The position accounts for ﹤0.01% of the portfolio, ranked #2638.

AQR Capital Management first reported a position in IBRX in Q3 2020 and has held it in 12 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • AQR Capital Management held 222,862 shares of ImmunityBio worth $1.95M as of Q2 2026.
  • AQR Capital Management bought 156,315 ImmunityBio shares in Q2 2026, an estimated $1.18M.
  • ImmunityBio made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #2638 holding.
  • AQR Capital Management first reported a position in ImmunityBio in Q3 2020 and has held it in 12 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.